Lawrence Lesko, director of the Office of Clinical Pharmacology and Biopharmaceutics in FDA's Center for Drug Evaluation and Research, said that the agency is working on guidance documents for clinical pharmacogenomics, clinical trial enrichment, and internal standard operating procedures for cross-labeling efforts within FDA offices.